Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Observational 3Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Breast Neoplasms 63Carcinoma, Non-Small-Cell Lung 60Rectal Neoplasms 44Glioblastoma 42Stomach Neoplasms 37Esophageal Neoplasms 33Brain Neoplasms 33Squamous Cell Carcinoma of Head and Neck 31Colorectal Neoplasms 29Pancreatic Neoplasms 26Lung Neoplasms 24Neoplasms 23Glioma 23Astrocytoma 22Neoplasm Metastasis 21Head and Neck Neoplasms 19Sarcoma 17Gliosarcoma 15Esophageal Squamous Cell Carcinoma 15Central Nervous System Neoplasms 15Ovarian Neoplasms 14Oligodendroglioma 13Melanoma 13Colonic Neoplasms 12Adenocarcinoma Of Esophagus 12Urinary Bladder Neoplasms 11Prostatic Neoplasms 11Carcinoma, Hepatocellular 11Oropharyngeal Neoplasms 9Carcinoma, Ovarian Epithelial 9

Interventions

Gemcitabine 111Cisplatin 75Oxaliplatin 43pembrolizumab 34Fluorouracil 31Capecitabine 30durvalumab 26Leucovorin 25lenvatinib 23Magnetic Resonance Spectroscopy 14Irinotecan 13Nivolumab 12Albumin-Bound Paclitaxel 12Specimen Handling 11Radiofrequency Ablation 11Drug Therapy 11Biopsy 11tislelizumab 10pemigatinib 10apatinib 10Taxes 10Floxuridine 10130-nm albumin-bound paclitaxel 10Radiotherapy 9Bevacizumab 9Folfox protocol 8Carboplatin 8tremelimumab 7atezolizumab 7S 1 (combination) 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Cholangiocarcinoma × Surgical Procedures, Operative × Clear all
NCT07208526 2025-10-06

A Randomized Trial of Surgical Decision-Making Guided by TDTP-RECIST

Shanghai Zhongshan Hospital

Phase NA Not yet recruiting
270 enrolled
Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT06721286 2024-12-06

Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Recruiting
70 enrolled
Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT05672537 2023-01-05

Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
70 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡